Cannabinoid antagonist SR-141716 inhibits endotoxic hypotension by a cardiac mechanism not involving CB1 or CB2 receptors.
about
The endocannabinoid system as an emerging target of pharmacotherapyIs the cardiovascular system a therapeutic target for cannabidiol?TRPV1 and SP: key elements for sepsis outcome?CB2 and GPR55 Receptors as Therapeutic Targets for Systemic Immune DysregulationTRPV1-mediated protection against endotoxin-induced hypotension and mortality in ratsIncreased fear- and stress-related anxiety-like behavior in mice lacking tuberoinfundibular peptide of 39 residues.The orexigenic effect of ghrelin is mediated through central activation of the endogenous cannabinoid system.Endotoxin impairs cardiac hemodynamics by affecting loading conditions but not by reducing cardiac inotropism.Early age-related cognitive impairment in mice lacking cannabinoid CB1 receptors.The effects of targeted deletion of cannabinoid receptors CB1 and CB2 on intranasal sensitization and challenge with adjuvant-free ovalbuminEffects of the novel cannabinoid CB1 receptor antagonist PF 514273 on the acquisition and expression of ethanol conditioned place preference.The cannabinoid receptor inverse agonist AM251 regulates the expression of the EGF receptor and its ligands via destabilization of oestrogen-related receptor α proteinCannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusionsBlood pressure regulation by endocannabinoids and their receptorsThe peripheral cannabinoid receptor knockout mice: an update.Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioningHemodynamic profile, responsiveness to anandamide, and baroreflex sensitivity of mice lacking fatty acid amide hydrolase.Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injuryCardiovascular pharmacology of cannabinoids.Beneficial effects of a novel ultrapotent poly(ADP-ribose) polymerase inhibitor in murine models of heart failure.TRPV1 ablation aggravates inflammatory responses and organ damage during endotoxic shockEffects of targeted deletion of cannabinoid receptors CB1 and CB2 on immune competence and sensitivity to immune modulation by Delta9-tetrahydrocannabinolThe future of endocannabinoid-oriented clinical research after CB1 antagonists.Endocannabinoids and cardiac contractile function: pathophysiological implications.Endocannabinoids and the heart.Anandamide mediates hyperdynamic circulation in cirrhotic rats via CB(1) and VR(1) receptors.Inhibitors of fatty acid amide hydrolase reduce carrageenan-induced hind paw inflammation in pentobarbital-treated mice: comparison with indomethacin and possible involvement of cannabinoid receptors.Involvement of CB1-receptors and beta-adrenoceptors in the regional hemodynamic responses to lipopolysaccharide infusion in conscious rats.Cannabinoids and EndotoxemiaLeft ventricular pressure-volume relationships during normal growth and development in the adult rat - studies in 8- and 50-week-old male Wistar rats
P2860
Q24648473-98F3B97A-3844-40EA-92F1-21E2C6DD3A61Q26865370-36060065-8B55-4B2E-92C8-C3EF757DB7EDQ27015036-CDC46714-BDBB-4C14-B2B0-DF28D1CE4270Q28072822-07E550EE-97F9-477C-9224-D183E73347EBQ28574345-BBBDB2FB-C52C-4399-8F25-18E7527AF365Q30485593-73BBAA1C-27FA-4DD6-90B1-B8092F7E031EQ33323392-996FA9A3-8683-4CB8-AB9A-C4F28AAEC8B5Q34092883-209EBF98-05CB-4E2E-A0A2-CE46CDBFE24DQ34098397-30E3BB6E-FED0-4D92-8271-21CAECACCD8AQ34136743-6D135B79-80C4-42F7-8C97-3B6DE3EE1797Q34301263-686268F5-ADA4-4228-A828-1EB064EFF324Q35376123-BF14D86B-86D4-4D1B-92F0-30EC60CC012BQ36052772-315DAAA1-4F79-4E05-9919-18E990E1BB3CQ36135785-1931394C-D6DD-45E7-9D3E-36054983A780Q36416347-7A91CAA0-2A0E-4352-89C7-9718BEF8EB22Q36416372-533F4DBE-37CC-458F-97F4-2320C486223EQ36426831-62839EE5-BC61-447B-9B48-23E2E89057D1Q36431793-9F5A165D-367A-4812-B0C9-08DC6298CD2CQ36431860-37AF48C3-0452-42E4-A291-267BE3A714C0Q36464461-5041F0C8-E50A-4872-A770-F8BD99FE1A0BQ36970244-28D0A31D-EA9A-4203-B513-39BB1FDF18E4Q37039010-FE11A146-EE01-43A9-9AC9-7A5B6C7CDDF6Q37226111-2166E393-AB0B-4C77-BA29-F699A301C365Q37401757-6815C5FE-1EA9-4EBC-A3F1-A71818E8F048Q37412217-3B79329F-EAF1-41F9-9997-4824F7400EF6Q41604550-7AFA7822-C56D-45EC-A63D-98AFDAA8707BQ41832173-98F06AD7-985D-489E-B576-7CBE054757DFQ45190193-C1A8D522-6366-4740-ACEF-A585CB23F567Q53395918-3E0B5E9E-6360-4197-BC5D-3ADE2B617099Q57298910-24B85587-4B33-4919-8BFE-703031009E23
P2860
Cannabinoid antagonist SR-141716 inhibits endotoxic hypotension by a cardiac mechanism not involving CB1 or CB2 receptors.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Cannabinoid antagonist SR-1417 ...... nvolving CB1 or CB2 receptors.
@en
type
label
Cannabinoid antagonist SR-1417 ...... nvolving CB1 or CB2 receptors.
@en
prefLabel
Cannabinoid antagonist SR-1417 ...... nvolving CB1 or CB2 receptors.
@en
P2093
P2860
P921
P1476
Cannabinoid antagonist SR-1417 ...... nvolving CB1 or CB2 receptors.
@en
P2093
George Kunos
Jens A Wagner
Sándor Bátkai
Zoltán Járai
P2860
P304
P356
10.1152/AJPHEART.00184.2004
P50
P577
2004-04-01T00:00:00Z